Separately, JMP Securities started coverage on Protagonist Therapeutics in a report on Thursday, August 25th. They set an outperform rating and a $21.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of Moderate Buy and an average price target of $43.71.
Protagonist Therapeutics Stock Up 4.5 %
Shares of NASDAQ PTGX opened at $8.38 on Tuesday. The firm’s 50-day simple moving average is $9.73 and its 200 day simple moving average is $12.94. The company has a market cap of $411.32 million, a price-to-earnings ratio of -3.06 and a beta of 2.56. Protagonist Therapeutics has a 12-month low of $6.91 and a 12-month high of $38.11.
Institutional Trading of Protagonist Therapeutics
A number of large investors have recently bought and sold shares of the business. ExodusPoint Capital Management LP acquired a new position in Protagonist Therapeutics during the 2nd quarter worth approximately $879,000. Walleye Capital LLC boosted its holdings in shares of Protagonist Therapeutics by 670.8% in the 2nd quarter. Walleye Capital LLC now owns 257,357 shares of the company’s stock valued at $2,036,000 after buying an additional 223,967 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Protagonist Therapeutics by 82.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 631,916 shares of the company’s stock valued at $4,999,000 after buying an additional 285,557 shares during the last quarter. Corton Capital Inc. acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at approximately $86,000. Finally, Delphia USA Inc. bought a new stake in Protagonist Therapeutics in the 2nd quarter valued at $94,000.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.
- Get a free copy of the StockNews.com research report on Protagonist Therapeutics (PTGX)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.